
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tafenoquine Succinate,SJ733
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
60 Degrees Pharma Grants University of Kentucky Right of Reference to ARAKODA® NDA
Details : Arakoda (tafenoquine succinate) is the inhibitor of hematin polymerization which is being evaluated with SJ733 for the treatment of P.vivax malaria.
Product Name : Arakoda
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 12, 2024
Lead Product(s) : Tafenoquine Succinate,SJ733
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SJ733
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : GHIT Fund
Deal Size : $5.4 million
Deal Type : Financing
Details : The financing will be used to develop a radical cure for P. vivax malaria. SJ000557733 (SJ733), an antimalarial drug candidate, has completed a Phase IIa trial for single administration and has shown efficacy and tolerability against P. vivax malaria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 13, 2023
Lead Product(s) : SJ733
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : GHIT Fund
Deal Size : $5.4 million
Deal Type : Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SJ733
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : R. Kiplin Guy
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria
Details : SJ733 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Malaria, Falciparum.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 14, 2021
Lead Product(s) : SJ733
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : R. Kiplin Guy
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SJ733
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Medicines for Malaria Venture | Eisai Inc | GHIT Fund
Deal Size : Inapplicable
Deal Type : Inapplicable
First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor
Details : SJ733 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Malaria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 22, 2016
Lead Product(s) : SJ733
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Medicines for Malaria Venture | Eisai Inc | GHIT Fund
Deal Size : Inapplicable
Deal Type : Inapplicable
